Microfluidic Dynamic Assays for In Vivo-Like Therapeutic Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional biochemical and biological assays fail to accurately mimic in vivo conditions, leading to inaccurate assessment of therapeutic reagents' efficacy and safety, especially for complex therapeutics like cell and gene therapies, due to the lack of dynamic fluid flow and physiologically relevant interactions.
Innovation Solution
A flow-based assay using microfluidic chips with channels of less than 100 μL volume, simulating physiological conditions by flowing therapeutic reagents over cultured target cells, mimicking shear stress and flow rates, and maintaining species-specific fidelity through controlled environments with gases like N2, O2, and CO2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional static in vitro assays are used, then the assay setup is simple and static, but the results fail to accurately represent in vivo conditions due to lack of dynamic fluid flow
Solution Approach 1:
The patent creates a microfluidic copy of in vivo physiological conditions by replicating blood flow dynamics, shear stress, and cellular interactions in a miniaturized chip environment. This copying approach allows accurate representation of complex in vivo processes without requiring actual in vivo testing, thereby improving measurement precision while controlling device complexity through scaling down.
Solution Approach 2:
The patent transforms the assay from static to dynamic by introducing controlled fluid flow parameters including flow rate, shear stress, and residence time. These parameter changes enable the system to mimic physiological conditions more accurately, improving the precision of therapeutic reagent assessment while the parameters remain controllable and measurable.
2Measurement precision
If animal models are used to represent in vivo conditions, then physiological relevance is improved, but species-specific differences reduce the accuracy for human therapeutic applications
Solution Approach 1:
The patent uses human-derived cells and biomolecules specifically within the microfluidic device, creating a localized human physiological environment. This allows the assay to be species-specific to humans while the microfluidic platform itself remains adaptable to different cell types and therapeutic agents, thereby improving measurement precision for human applications without sacrificing versatility.
Solution Approach 2:
The microfluidic device serves as an intermediary system that bridges the gap between in vitro simplicity and in vivo complexity. By using human cells within the controlled microfluidic environment, the system provides a human-specific platform that avoids species-specific differences of animal models while maintaining the versatility to test various therapeutic agents.
3Measurement precision
If microfluidic channels with small volume are used, then physiologically-relevant flow conditions are achieved, but the volume of therapeutic reagent and cells required is reduced
Solution Approach 1:
The patent employs disposable microfluidic chips with integrated channels that require minimal volumes of expensive therapeutic reagents and rare cells. The small channel volumes (typically nanoliter to microliter scale) enable high-fidelity physiological simulation while consuming minimal amounts of valuable substances, making the assay both precise and resource-efficient.
4Measurement precision
If dynamic flow conditions are introduced, then in vivo physiological relevance is improved, but the complexity of controlling flow parameters increases
Solution Approach 1:
The patent introduces dynamic flow conditions through controlled pumping systems that can adjust flow rate, direction, and timing to mimic physiological pulsatile flow patterns. The microfluidic device incorporates dynamic elements such as valves and flow regulators that enable precise control of flow parameters while maintaining overall system manageability through automated control.
Solution Approach 2:
The system incorporates sensors and control mechanisms that monitor flow parameters and provide feedback to maintain physiological relevance. By using feedback control, the system can automatically adjust flow conditions to match target physiological parameters, improving measurement precision while reducing the complexity of manual control through automated regulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides more accurate and representative results by simulating in vivo conditions, enhancing the assessment of therapeutic reagents' efficacy and safety, particularly for cell and gene therapies, by capturing interactions under physiologically relevant conditions.
Implementation Method 1
flowing the test liquid over the cultured target cells in at least one of the channel(s)
Implementation Method 2
mimicking the dynamic flow that occurs in, for example, blood circulation, the physiologically-relevant shear stress on the target
Implementation Method 3
heating the target cells and/or therapeutic reagent(s)
Implementation Method 4
supplying a physiologically-relevant gas (e.g., comprising nitrogen (N2), oxygen (O2), carbon dioxide (CO2), and/or compressed air) to a chamber in which the microfluidic chip(s) are disposed
Data Source
AI summary
Some methods of performing an assay comprise culturing target cells in one or more channels of one or more microfluidics chips, where each of the channel(s) can have a volume that is less than or equal to 100 microliters (μL). For each of one or more test liquids that each comprise a therapeutic reagent, the test liquid can flow over the cultured target cells in at least one of the channel(s) and, while the test liquid flows over the cultured target cells, data indicative of an interaction between the target cells over which the test liquid flows and the therapeutic reagent of the test liquid can be captured.